These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 20192985)

  • 1. The proteasome inhibitor bortezomib inhibits FGF-2-induced reduction of TAZ levels in osteoblast-like cells.
    Eda H; Aoki K; Kato S; Okawa Y; Takada K; Tanaka T; Marumo K; Ohkawa K
    Eur J Haematol; 2010 Jul; 85(1):68-75. PubMed ID: 20192985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The proteasome inhibitor bortezomib stimulates osteoblastic differentiation of human osteoblast precursors via upregulation of vitamin D receptor signalling.
    Kaiser MF; Heider U; Mieth M; Zang C; von Metzler I; Sezer O
    Eur J Haematol; 2013 Apr; 90(4):263-72. PubMed ID: 23311753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients.
    Giuliani N; Morandi F; Tagliaferri S; Lazzaretti M; Bonomini S; Crugnola M; Mancini C; Martella E; Ferrari L; Tabilio A; Rizzoli V
    Blood; 2007 Jul; 110(1):334-8. PubMed ID: 17371942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FGF-2 signaling induces downregulation of TAZ protein in osteoblastic MC3T3-E1 cells.
    Eda H; Aoki K; Marumo K; Fujii K; Ohkawa K
    Biochem Biophys Res Commun; 2008 Feb; 366(2):471-5. PubMed ID: 18067853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FGF2 stimulates osteogenic differentiation through ERK induced TAZ expression.
    Byun MR; Kim AR; Hwang JH; Kim KM; Hwang ES; Hong JH
    Bone; 2014 Jan; 58():72-80. PubMed ID: 24125755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo.
    Pennisi A; Li X; Ling W; Khan S; Zangari M; Yaccoby S
    Am J Hematol; 2009 Jan; 84(1):6-14. PubMed ID: 18980173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of osteoblastic differentiation by the proteasome inhibitor bortezomib.
    Uyama M; Sato MM; Kawanami M; Tamura M
    Genes Cells; 2012 Jul; 17(7):548-58. PubMed ID: 22702336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-line treatment with bortezomib rapidly stimulates both osteoblast activity and bone matrix deposition in patients with multiple myeloma, and stimulates osteoblast proliferation and differentiation in vitro.
    Lund T; Søe K; Abildgaard N; Garnero P; Pedersen PT; Ormstrup T; Delaissé JM; Plesner T
    Eur J Haematol; 2010 Oct; 85(4):290-9. PubMed ID: 20528908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment.
    Heider U; Kaiser M; Müller C; Jakob C; Zavrski I; Schulz CO; Fleissner C; Hecht M; Sezer O
    Eur J Haematol; 2006 Sep; 77(3):233-8. PubMed ID: 16923110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bortezomib enhances the osteogenic differentiation capacity of human mesenchymal stromal cells derived from bone marrow and placental tissues.
    Sanvoranart T; Supokawej A; Kheolamai P; U-Pratya Y; Klincumhom N; Manochantr S; Wattanapanitch M; Issaragrisil S
    Biochem Biophys Res Commun; 2014 May; 447(4):580-5. PubMed ID: 24747566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Constitutive down-regulation of Osterix in osteoblasts from myeloma patients: in vitro effect of Bortezomib and Lenalidomide.
    De Matteo M; Brunetti AE; Maiorano E; Cafforio P; Dammacco F; Silvestris F
    Leuk Res; 2010 Feb; 34(2):243-9. PubMed ID: 19656567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bortezomib induces osteoblast differentiation via Wnt-independent activation of beta-catenin/TCF signaling.
    Qiang YW; Hu B; Chen Y; Zhong Y; Shi B; Barlogie B; Shaughnessy JD
    Blood; 2009 Apr; 113(18):4319-30. PubMed ID: 19196662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activating transcription factor 4, an ER stress mediator, is required for, but excessive ER stress suppresses osteoblastogenesis by bortezomib.
    Nakamura S; Miki H; Kido S; Nakano A; Hiasa M; Oda A; Amou H; Watanabe K; Harada T; Fujii S; Takeuchi K; Kagawa K; Ozaki S; Matsumoto T; Abe M
    Int J Hematol; 2013 Jul; 98(1):66-73. PubMed ID: 23708974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects.
    Hurchla MA; Garcia-Gomez A; Hornick MC; Ocio EM; Li A; Blanco JF; Collins L; Kirk CJ; Piwnica-Worms D; Vij R; Tomasson MH; Pandiella A; San Miguel JF; Garayoa M; Weilbaecher KN
    Leukemia; 2013 Feb; 27(2):430-40. PubMed ID: 22763387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stimulation of new bone formation by the proteasome inhibitor, bortezomib: implications for myeloma bone disease.
    Oyajobi BO; Garrett IR; Gupta A; Flores A; Esparza J; Muñoz S; Zhao M; Mundy GR
    Br J Haematol; 2007 Nov; 139(3):434-8. PubMed ID: 17910634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bortezomib upregulates [corrected] the osterix expression by osteoblasts in the myeloma microenvironment: Implications into osteoblast function in myeloma bone disease.
    Terpos E
    Leuk Res; 2010 Jun; 34(6):700-1. PubMed ID: 20074800
    [No Abstract]   [Full Text] [Related]  

  • 17. Transient suppression of core-binding factor alpha 1 expression by basic fibroblast growth factor in rat osteoblast-like osteosarcoma ROS17/2.8 cells.
    Tsuji K; Noda M
    J Bone Miner Metab; 2001; 19(4):213-9. PubMed ID: 11448013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
    Li X; Wood TE; Sprangers R; Jansen G; Franke NE; Mao X; Wang X; Zhang Y; Verbrugge SE; Adomat H; Li ZH; Trudel S; Chen C; Religa TL; Jamal N; Messner H; Cloos J; Rose DR; Navon A; Guns E; Batey RA; Kay LE; Schimmer AD
    J Natl Cancer Inst; 2010 Jul; 102(14):1069-82. PubMed ID: 20505154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EZH2 or HDAC1 Inhibition Reverses Multiple Myeloma-Induced Epigenetic Suppression of Osteoblast Differentiation.
    Adamik J; Jin S; Sun Q; Zhang P; Weiss KR; Anderson JL; Silbermann R; Roodman GD; Galson DL
    Mol Cancer Res; 2017 Apr; 15(4):405-417. PubMed ID: 28119431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensitizing human multiple myeloma cells to the proteasome inhibitor bortezomib by novel curcumin analogs.
    Mujtaba T; Kanwar J; Wan SB; Chan TH; Dou QP
    Int J Mol Med; 2012 Jan; 29(1):102-6. PubMed ID: 22012631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.